NEW YORK, Oct. 14, 2005 (PRIMEZONE) -- Bioaccelerate Holdings Inc, (OTCBB:BACL) announces that it has appointed Ronald A. Martell to its Board of Directors.
Ronald Martell currently serves as ImClone Systems Incorporated's Senior Vice President, Commercial Operations, where his responsibilities include overseeing the company's sales, marketing, project and alliance management. He also leads ImClone Systems' strategic and corporate planning and development and is a member of the company's Management Committee. Mr. Martell is also responsible for extensive interaction with ImClone Systems' external audiences, including senior level medical educators, physicians, pharmaceutical, commercial and R&D executives as well as Wall Street.
Since joining ImClone Systems in 1998, Mr. Martell has successfully built the company's commercial operations department, including a 49 person field force, and launched its first commercial product, Erbitux(r). He will serve on Bioaccelerate's board of directors alongside his position at ImClone Systems.
Prior to joining ImClone Systems, Mr. Martell served as Group Manager, Oncology Products, for Genentech, Inc. While at Genentech, his department directed the launch of two breakthrough biologic therapies, Herceptin(r) and Rituxan(r), and was responsible for managing or supporting all stages of product development for a variety of programs within the company's oncology and specialty biotherapeutics divisions.
About Bioaccelerate
Bioaccelerate Holdings Inc. (OTCBB:BACL) is a pharmaceutical development organization ("PDO") that seeks to acquire, develop and commercialize novel pharmaceutical compounds in an efficient, cost-effective way. Bioaccelerate uses its broad network of academic, industry and capital market relationships to expedite drug development and raise capital to create and fund its subsidiary companies, which are organized by vertical portfolios in five therapeutic areas: oncology, specialty pharmaceuticals, central nervous system disorders (CNS), cardiovascular disease and anti-infectives.
Bioaccelerate conducts its business directly and through its subsidiaries. The company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate's strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin Board under the symbol "BACL." For more information on Bioaccelerate, visit the company's website at http://www.bioaccelerate.com.
Bioaccelerate Safe Harbor Statement
Certain statements contained herein are "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to: risks associated with pre-clinical and clinical developments in the biopharmaceutical industry in general and in Bioaccelerate's compounds under development in particular; the potential failure of Bioaccelerate's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Bioaccelerate's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Bioaccelerate's business, structure or projections; the development of competing products; uncertainties related to Bioaccelerate's dependence on third parties and partners; and those risks described in the filings with the SEC, all of which are under Bioaccelerate's prior name Mobile Design Concepts, Inc. Bioaccelerate disclaims any obligation to update these forward-looking statements.